These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1080 related articles for article (PubMed ID: 9886380)

  • 1. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
    Schnell S; Young JW; Houghton AN; Sadelain M
    J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A; Snyder D; Gilboa E
    J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
    Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
    Specht JM; Wang G; Do MT; Lam JS; Royal RE; Reeves ME; Rosenberg SA; Hwu P
    J Exp Med; 1997 Oct; 186(8):1213-21. PubMed ID: 9334360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
    Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
    Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar immune responses and antitumor effects of murine dendritic cells loaded with either exogenous or endogenous-synthesized protein.
    Lacave R; Masurier C; Guigon M; Lemoine FM; Klatzmann D; Colombo BM
    Int J Oncol; 2003 Dec; 23(6):1747-53. PubMed ID: 14612950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
    J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization of retrovirus-transfected dendritic cells induces specific cytotoxic T lymphocytes for two distinct malarial peptides presented by Kd molecule.
    Hetttihewa LM
    Int Immunopharmacol; 2003 Oct; 3(10-11):1401-11. PubMed ID: 12946436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
    Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
    J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
    Herrera OB; Brett S; Lechler RI
    Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation.
    Krasteva M; Kehren J; Horand F; Akiba H; Choquet G; Ducluzeau MT; Tédone R; Garrigue JL; Kaiserlian D; Nicolas JF
    J Immunol; 1998 Feb; 160(3):1181-90. PubMed ID: 9570532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
    Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
    J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.